Gilead Sciences
Clinical trials sponsored by Gilead Sciences, explained in plain language.
-
New drug GS-2426 targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests the safety of a new drug called GS-2426 in people with advanced solid tumors that lack a gene called MTAP. About 174 adults whose cancer has worsened after standard treatments will receive the drug. The main goal is to find the safest dose and check f…
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
New hope for Hard-to-Treat colorectal cancer? trial launches
Disease control Not yet recruitingThis study tests a new drug called denikitug, alone or with other medicines, in people with advanced colorectal cancer that is microsatellite stable (MSS). MSS tumors often don't respond to standard immunotherapy. The goal is to see if these combinations can shrink tumors or slow…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 26, 2026 03:52 UTC